Connect with us

Featured

Ever Hear Of Connecting The Dots? Consider This Your Heads Up

Joe Samuel

Published

on

stock market today

In the stock market, investors have been cautious following the massive volatility we’ve seen this quarter.  This can make it very difficult to navigate the waters of the stock market. StockPrice.com is here to help.  Every day we’re sourcing the most actionable insight on market sentiment and to date, we’ve done a very good job of finding out the real story behind Wall Street headlines.  We’ve cut through a lot of the “proverbial crap” that unfortunately other financial outlets find a need to add to their commentary.

The long and short of it is this: We’ve been building a great site and have been paying very close attention to what the market (and investors) like right now. So in true fashion, we think it’s fitting to connect the dots for our subscribers and loyal readers.

What does that actually mean? Well, right now attention seems to be focused on one particular sector of the market and within that sector, there’s a particular niche that we feel has been targeted as a new opportunity for investors and we want to connect the dots for you. To put it in simpler terms, let’s post these questions:

  1. If someone were to tell you to pay attention to a small company called Turtle Beach (HEAR) a year ago, would you have listened? That stock was trading around $2 but anyone with access to a time machine today would gladly go back and take a second look after seeing shares of HEAR hit $34.50 this year & currently trade above $17 even with the market volatility.
  2. Or even better, what if you had known about Tandem Diabetes Care (TNDM) when it was trading under $3 earlier this year? Well, we’re sure that if you knew how to connect the dots during the first quarter, you would have been ahead of the curve before Tandem jumped to more than $50 a share.
  3. CareDx (CDNA) was trading under $6 this year but those who read between the lines are looking at a stock now trading above $25 and one that has seen highs of nearly $30 and it hasn’t even been a full year yet.
  4. How about this one for those doubters of stocks under $1: 3Pea International was only $0.75 on January 25 and was barely trading any daily volume. Today, those who connected the dots back then would see a position that’s now up by more than 400% in less than 8 months.
  5. And another “penny stock,” NII Holdings (NIHD) was trading under $0.50 at the beginning of the year. It has since managed to reach highs of $7.29 and currently trades above $6 per share; a potential windfall of more than 1,600%.

But why mention these companies that media outlets such as CNBC or Fox Business aren’t talking about? Simple, THEY AREN’T TALKING ABOUT THEM and mainstream investors are missing out in a big way.

Sure we could be like everyone else and point out how people could have made big money on Amazon 10 years ago or Apple over 30 years ago but let’s get real here, when it comes to the market, who wants to wait that long when you can clearly see that 500%, 1,000%, and even 1,600%+ moves aren’t as uncommon as you may think…

You just need to be able to connect the dots early and be ready for the ride as we’ve seen above. Now, we’re a new site but we’ve been in the markets for a very long time and we can say & show you countless examples like these.  The companies that aren’t mainstream and maybe even trade on light volume early on. But as you can clearly see just from these few examples, the snowball effect is a real thing and connecting the dots early on can be the difference between a Ford F150 and a Ferrari F12.

What if there was an opportunity to see these companies at those levels; what would you do if the dots were connect for you?  The obvious answer (in my opinion) would be “I would definitely buy”. A small investment at a price like these would be absolutely life changing at today’s prices, let alone at the 2018 highs that these stocks have seen over the last 10 months.

Within the next few days, we are going to introduce and connect the dots on one company that has just come to light with a very strong team, recent news, all coupled with a similar vision and groundbreaking technology that is on the bleeding edge of a major industry shift. In looking at the share structure, stock price, and market cap, this company looks like it could have what it takes to captivate the public. 

We pride ourselves in finding companies that have staying power and longevity, not just a simple “one-day wonder”. We live, breathe, eat, sleep the stock market so sit back, relax, and let us do the dirty work because we are just getting started and will be connecting the dots on a new public company in the very near future. 

Consider this your “heads up.

Continue Reading
1 Comment

Featured

4 Security Penny Stocks To Watch

A. Lawrence

Published

on

As Threats Arise, Security Stocks Take Center Stage In 2019

With the Federal Reserve’s meeting coming, the general market is bracing for anything. Meanwhile, penny stocks are continuing to climb at absurd rates. Trading penny stocks as of late has brought many investors fruitful profits and they look to continue this trend. Here are some security penny stocks to watch for the remainder of June 2019:

Security Penny Stock #1
Liberty Defense Holdings (SCAN.V)
Market Cap: $46.404M

Liberty Defense Holdings Ltd. (SCAN.V) is a security company looking to take the industry into the next century. Liberty’s HEXWAVE product is a 3-dimensional scanning device that can detect weapons and threats of any kind. The product can do this both with speed and discretion ensuring privacy for citizens.

Liberty signed a Memorandum of Understanding with the soccer team FC Bayern München to beta test HEXWAVE in their arena. They join an ever-growing list of places that have signed MOU’s to beta test Liberty’s product. This MOU expands its ability to comply with and test the market requirements for their product internationally.

“The reception to our HEXWAVE product has been fantastic and we are excited about working alongside FC Bayern Munich, a team that is a household name in both Europe and North America, […] Our ability to deploy in both indoor and outdoor settings, with covert and overt applications, sets us apart and has also been driving increasing interest from the market.” 

Bill Riker, CEO of Liberty

Security Penny Stock #2
Magal Security Systems (MAGS)
Market Cap: $101.371M

Magal Security Systems Ltd. (MAGS) provides security solutions both online and physical. Some services provided include identifying potential security problems, integrating new systems, and custom designs for any type of security needs.

Recently, Magal received a $5.5 million contract for its advanced perimeter intrusion detection system. The system prevents people from illegally crossing border fences and walls.

Dror Sharon, CEO of Magal, stated, “Magal is a world leader in perimeter intrusion technologies. Our growing wins of orders such as this – providing sensors for active international borders, is due to the decades of experience that we have in providing systems that have more than proven themselves in-the-field.”


Security Penny Stock #3
Rekor Systems (REKR)
Market Cap: $27.502M

Rekor Systems Inc. (REKR) is a company that has developed surveillance technology to enhance public safety, banking, and traffic management. Primarily, the company takes their advanced software, which utilizes machine learning and upgrades IP cameras to the next level. This reduces the cost when collecting highway tolls and helps manage traffic congestion.

REKR stock chart

Throughout June, Rekor Systems has been gaining recognition and application across the US. On June 3rd Rekor obtained a contract to start deploying its Mobile LBR-2 vehicle recognition systems. After this deployment on the 3rd, the LPR-2 system North Carolina law enforcement placed an order. On June 12th, Colorado highway authorities chose Rekor’s cloud system called NUMERUS to read enhance their license plate reading.


Security Penny Stock #4
BIO-key International (BKYI)
Market Cap: $18.03M

BIO-key International Inc. (BKYI) is a security technologies company that is pushing past the limits of fingerprint scanning. BIO-key provides a plethora of finger scanning products that provide security for your computer, hard drive, and the government. They have a partnership with Microsoft to develop biometric sign-in for Windows 10.

The company recently announced that a foreign defense ministry ordered more BIO-key deployment for secure access to Microsoft applications.

“We were delighted that such a capable and prestigious technology team determined that BIO-key met their security and scalability requirements and have now made follow-on investments to grow their user base.  Defense Ministries are constant targets of cyber-attacks, and we are glad to help them step up authentication to the highest assurance with NIST-verified accuracy and FIPS compliance.”

Jim Sullivan, SVP of BIO

security stocks
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 04/15/2018 – 5/15/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter now extended through June 21, 2019. We were paid $350,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE

Continue Reading

Featured

Stock Price Pre Market Update – June 19, 2019

Joe Samuel

Published

on

Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks

Click For Full Article


How Tech Is Making Life Easier?

The Answer Is ONE CLICK Away


Healthcare Penny Stocks To Watch

See For Yourself


Is Palatin Technologies (PTN) A Penny Stock To Buy Or Sell?

You Decide, Click Here

Continue Reading

Biotechnology

Is Palatin Technologies (PTN) A Penny Stock To Buy Or Sell?

Joe Samuel

Published

on

Will Shares Of Palatin Technologies (PTN) Head Higher As Biotech Stocks Rally This Month?

Biotech stocks are rallying this month.  Despite the “pop and drop” this sector saw earlier in the year, June has been a big month for biotechnology companies and people investing in this sector. 

IBB ETF chart

In fact, the iShares Trust Biotechnology ETF (IBB) has climbed by more than 8% since the start of June. This sector has been famous for producing volatile returns for investors. Furthermore, biotech penny stocks have increased that potential.

Palatin Technologies (PTN) Is A Biotech Penny Stock To Watch

One of the best performing penny stocks in the biotechnology sector this month has been Palatin Technologies Inc. (PTN). On January 2, this penny stock opened the year at $0.71 and has seen a 2019 high of $1.74. What’s more is that even though PTN stock has consolidated, it has continued to trade above $1.20.

So what’s all the excitement about? Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.

The company’s main strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.

[New Research] Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks

The recent excitement seems to have started in April after the company reported positive top-line results of its oral clinical study of PL-8177. The treatment is designed to address ulcerative colitis and other inflammatory bowel diseases.

“The main objective of the study was to demonstrate release of polymer-bound PL-8177 in the lower gastrointestinal tract after oral administration. Top line data showed favorable pharmacokinetics, and demonstrated PL-8177 was released in the lower gastrointestinal tract, supporting oral administration of PL-8177 using the delayed release polymer formulation.”

New Milestones From Palatine Technologies (PTN) Triggers New Highs

After hitting new highs on May 17th after posting quarterly earnings, shares of PTN stock have consolidated. Regardless, the company continues to progress. Earlier this month the company obtained orphan drug designation for PL-8177. Yes, this is the same one that I talked about above when the company received positive topline results earlier in the year.

Why is orphan drug designation important? This is a good question especially if you’re newer to biotech penny stocks or biopharmaceutical stocks, in general. In the exact words of the FDA:

“The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor. This status is referred to as orphan designation (or sometimes “orphanstatus”).”

Essentially it gives companies incentives above and beyond competitors. These incentives include a partial tax credit for clinical trial expenditures, waived user fees, and eligibility for 7 years of marketing exclusivity. The obvious response would be favorable, which has been seen in the market over the past few trading sessions.

Dr. Carl Spana, President and Chief Executive Officer of Palatin Technologies, said in a press release, “Unlike corticosteroids, immunosuppressive agents, and biological therapies targeting specific cytokines or receptors, melanocortin receptor 1 peptides work to resolve chronic inflammations and restore normal immune function. We look forward to initiating clinical trials with PL-8177 for non-infectious uveitis, a high medical need disease with limited treatment options.”

But Here’s Why Palatin Might Be Set For More Excitement

It’s all about sex drive. You read that right. And something that hasn’t really been fully publicized is this “big FDA date.” You see on June 23rd, the application for Vyleesi (bremelanotide), a drug developed by Palatin and licensed to AMAG Pharmaceuticals (AMAG) will be up for review by the FDA as a New Drug.

Vyleesi is a novel melanocortin 4 receptor agonist under evaluation for restoring a natural sexual desire in premenopausal women with HSDD. Think of this like female Viagra. Will this become the sexiest biotech penny stock this month or will stock traders get blue balled?

Like This Article? Check Out: Small Cap Biotech Stocks See Boost From Large Cap M&A

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com